CMET in triple-negative breast cancer: Is it a therapeutic target for this subset of breast cancer patients?

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 9, 2014, Pages 999-1009

  Gaule, Patricia B ^a   Crown, John ^a,b   O'Donovan, Norma ^a   Duffy, Michael J ^b,c  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Basal; Breast cancer; CMET; Targeted therapy; Triple negative

Indexed keywords

BIOLOGICAL MARKER; CABOZANTINIB; FICLATUZUMAB; MONOCLONAL ANTIBODY; ONARTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; TIVANTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

BASAL LIKE BREAST CANCER; BREAST CANCER; CMET ONCOGENE; HUMAN; ONCOGENE; REVIEW; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906272707     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.938050     Document Type: Review

References (80)

1. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011;378(9805):1812-23
2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869-74
3. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100(14):8418-23
4. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2005;19(2):264-71
5. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116(3):340-50
6. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10(16):5367-74
7. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82(11):1525-33
8. Siziopikou KP, Ariga R, Proussaloglou KE, et al. The challenging estrogen receptor-negative/progesterone receptor-Negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J 2006;12(4):360-2
9. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502(7471):333-9
10. Foulkes WD, Smith IE, Reis-Filho J. Triple-negative breast cancer. N Engl J Med 2010;363(20):1938-48
11. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121(7):2750-67
12. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2011;16(Suppl 1):71-8
13. Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 2012;131(11):2471-7
14. Graveel CR, DeGroot JD, Su Y, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009;106(31):12909-14
15. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth Factor - cMET axis in cancer therapy. J Clin Oncol 2012;30(26):3287-96
16. Graveel CR, Tolbert D, Vande Woude GF. MET: A critical player in. tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol 2013;5(7): doi:10. 1101/cshperspect. a009209
17. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311(5981):29-33
18. Park M, Dean M, Kaul K, et al. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci USA 1987;84(18):6379-83
19. Gautam M, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13(1):41-59
20. Tempest PR, Stratton MR, Cooper CS. Structure of the met protein and variation of the met protein kinase activity among human tumour cell lines. Br J Cancer 1988;58(1):3-7
21. Nakamura T, Nawa K, Ichihara A, et al. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 1987;224(2):311-16
22. Tolbert WD, Daugherty-Holtrop J, Gherardi E, et al. Structural basis for agonism and antagonism of hepatocyte growth factor. Proc Natl Acad Sci USA 2010;107(30):13264-9
23. Naldini L, Vigna E, Ferracini R, et al. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol 1991;11(4):1793-803
24. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010;46(7):1260-70
25. Schmidt L, Duh F, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16(1):68-73
26. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/Hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999;59(2):307-10
27. Lee J, Han S, Cho H, et al. A novel germline juxtamembrane met mutation in human gastric cancer. Oncogene 2002;19(43):4947-53
28. Michieli P, Basilico C, Pennacchietti S, et al. Mutant met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999;18(37):5221-31
29. Koeppen H, Rost S, Yauch RL. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors. J Pathol 2014;232(2):210-18
30. Toschi L, Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010;6(2):239-47
31. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalling. Science 2007;316(5827):1039-43
32. Tuck AB, Park M, Sterns EE, et al. Coexpression of hepatocyte growth factor and receptor (met) in human breast carcinoma. Am J Pathol 1996;148(1):225-32
33. Lindemann K, Resau J, Nährig J, et al. Differential expression of c-met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology 2007;51(1):54-62
34. Raghav KP, Wang W, Liu S, et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 2012;18(8):2269-77
35. Carracedo A, Egervari K, Salido M, et al. FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-met) in 184 invasive breast tumors. Breast Cancer Res 2009;11(2):R402
36. Beviglia L, Matsumoto K, Lin C, et al. Expression of the C-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 1997;74(3):301-9
37. Edakuni G, Sasatomi E, Satoh T, et al. Expression of the hepatocyte growth factor/c-met pathway is increased at the cancer front in breast carcinoma. Pathol Int 2001;51(3):172-8
38. Garcia S, Dales JP, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 2007;38(6):830-41
39. Garcia S, Dales JP, Charafe-Jauffret E, et al. Overexpression of c-met and of the transducers PI3K, FAK, JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 2007;31(1):48-58
40. Lengyel E, Prechtel D, Resau JH, et al. C-met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/ neu. Int J Oncol 2005;113(4):678-82
41. Kang JY, Dolled-Filhart M, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth Factor/Met pathway components reveals a role for met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003;63(5):1101-5
42. Ho-Yen CM, Green AR, Rakha EA, et al. C-met in invasive breast cancer. Cancer 2014;120(2):163-71
43. Kim YJ, Choi J, Seo J, et al. MET is a potential target for use in combination therapy with EGFR inhibition in triplenegative/ basal-like breast cancer. Int J Cancer 2014;134(10):2424-36
44. Tashiro K, Hagiya M, Nishizawa T, et al. Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc Natl Acad Sci USA 1990;87(8):3200-4
45. Yao Y, Jin L, Fuchs A, et al. Scatter factor protein levels in human breast cancers. Am J Pathol 1996;149(5):1707-17
46. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54(7):1630-3
47. Ponzo MG, Lesurf R, Petkiewicz S, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009;106(31):12903-8
48. Knight JF, Lesurf R, Zhao H, et al. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci USA 2013;110(14):E1301-10
49. Hochgräfe F, Zhang L, O'Toole SA, et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res 2010;70(22):9391-401
50. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2005;25(15):2273-84
51. Gonçalves A, Charafe-Jauffret E, Bertucci F, et al. Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 2008;7(8):1420-33
52. Gastaldi S, Comoglio P, Trusolino L. The met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res 2010;12(4):208
53. Gaule P, Collins D, Walsh N, et al. Met and HGF inhibition in triple-negative breast cancer cell lines. J Clin Oncol 2011;31(Suppl):abstract 1066
54. Mueller KL, Hunter LA, Ethier SP, et al. Met and c-src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008;68(9):3314-22
55. Mueller K, Yang Z, Haddad R, et al. EGFR/Met association regulates EGFR TKI resistance in breast cancer. J Mol Signal 2010;5(1):8
56. Mueller KL, Madden JM, Zoratti GL, et al. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of met. Breast Cancer Res 2012;14(4):R104
57. Gartner E, Kim E, L Choi L, et al. Preclinical efficacy of the combination of met and src family kinase inhibitors in triple negative breast cancer. Cancer Res 2011;71(24 Suppl):abstract PD08-08
58. Finkbeiner MR, Astanehe A, To K, et al. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009;28(11):1421-31
59. Stratford A, Habibi G, Astanehe A, et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 2007;9(5):R61
60. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 2011;103(8):645-61
61. Sun B, Liu R, Xiao Z, et al. c-MET protects breast cancer cells from apoptosis induced by sodium butyrate. PLoS One 2012;7(1):e30143
62. Huang S, Ouyang N, Lin L, et al. HGF-induced PKCz activation increases functional CXCR4 expression in human breast cancer cells. PLoS One 2012;7(1):e29124
63. Previdi S, Abbadessa G, Dalò F, et al. Breast Cancer-Derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 2012;11(1):214-23
64. Prat M, Crepaldi T, Pennacchietti S, et al. Agonistic monoclonal antibodies against the met receptor dissect the biological responses to HGF. J Cell Sci 1998;111(2):237-47
65. Merchant M, Ma X, Maun HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA 2013;110(32):E2987-96
66. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non - small-cell lung cancer. J Clin Oncol 2013;31(32):4105-14
67. Media release [Internet]. 2014. Available from: http://www. roche. com/media/media-releases/med-cor- 2014-03-03. htm
68. Dieras V, Yardley D, Romieu G, et al. A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC). Cancer Res 2013;73:abstract P2-16-01
69. Goldman JW, Rosen LS, Algazi AP, et al. First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer. J Clin Oncol 2013;31(Suppl): abstract 1066
70. Yan SB, Um SL, Peek VL, et al. Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors. Cancer Res 2012;72(8 Suppl):abstract 1738
71. Martin LP, Sill M, Shahin MS, et al. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 2014;132(3):526-30
72. Katayama R, Aoyama A, Yamori T, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013;73(10):3087-96
73. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9(6):1544-53
74. Rayson D, Lupichuk SM, Chia SK, et al. A phase II study of foretinib in triple negative, recurrent/metastatic breast cancer: NCIC CTG trial IND. 197 (NCT01147484). J Clin Oncol 2012;30(Suppl):abstract 1036
75. Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment for cancer. Clin Chem 2013;59(10):1447-56
76. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23(9):1803-10
77. Soria J, Mok TS, Cappuzzo F, et al. EGFR-mutated oncogene-addicted nonsmall cell lung cancer: current trends and future prospects. Cancer Treat Rev 2012;38(5):416-30
78. Koeppen H, Yu W, Zha J, et al. Biomarker analyses from a placebocontrolled phase II study evaluating erlotinib ± onartuzumab in advanced non-small-cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 2014; [Epub ahead of print]
79. Huh C, Factor VM, Sánchez A, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004;101(13):4477-82
80. Http://clinicaltrials. gov/[Internet]. 2014. Available from: http://clinicaltrials. gov/